1. Home
  2. GRI vs CETX Comparison

GRI vs CETX Comparison

Compare GRI & CETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRI
  • CETX
  • Stock Information
  • Founded
  • GRI 2018
  • CETX 1998
  • Country
  • GRI United States
  • CETX United States
  • Employees
  • GRI 4
  • CETX N/A
  • Industry
  • GRI Biotechnology: Pharmaceutical Preparations
  • CETX EDP Services
  • Sector
  • GRI Health Care
  • CETX Technology
  • Exchange
  • GRI Nasdaq
  • CETX Nasdaq
  • Market Cap
  • GRI 4.8M
  • CETX 4.1M
  • IPO Year
  • GRI N/A
  • CETX 1998
  • Fundamental
  • Price
  • GRI $1.93
  • CETX $0.66
  • Analyst Decision
  • GRI Strong Buy
  • CETX
  • Analyst Count
  • GRI 2
  • CETX 0
  • Target Price
  • GRI $22.00
  • CETX N/A
  • AVG Volume (30 Days)
  • GRI 3.2M
  • CETX 1.1M
  • Earning Date
  • GRI 11-13-2025
  • CETX 08-14-2025
  • Dividend Yield
  • GRI N/A
  • CETX N/A
  • EPS Growth
  • GRI N/A
  • CETX N/A
  • EPS
  • GRI N/A
  • CETX N/A
  • Revenue
  • GRI N/A
  • CETX $76,095,551.00
  • Revenue This Year
  • GRI N/A
  • CETX $19.77
  • Revenue Next Year
  • GRI N/A
  • CETX $15.00
  • P/E Ratio
  • GRI N/A
  • CETX N/A
  • Revenue Growth
  • GRI N/A
  • CETX 16.50
  • 52 Week Low
  • GRI $1.10
  • CETX $0.60
  • 52 Week High
  • GRI $30.43
  • CETX $381.57
  • Technical
  • Relative Strength Index (RSI)
  • GRI 63.28
  • CETX 21.82
  • Support Level
  • GRI $1.76
  • CETX $0.60
  • Resistance Level
  • GRI $2.07
  • CETX $0.92
  • Average True Range (ATR)
  • GRI 0.22
  • CETX 0.08
  • MACD
  • GRI 0.05
  • CETX -0.03
  • Stochastic Oscillator
  • GRI 37.75
  • CETX 9.91

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About CETX Cemtrex Inc.

Cemtrex Inc is a multi-industry technology company. It has expanded in a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security system. The company's operating segment includes, Security segment, Industrial Services segment and the corporate segment. The security segment provides end to end security to all industrial, corporate and governmental security via owned subsidiary Vicon. Whereas AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment. It geographically operates in USA, UK and India, with maximum of revenue from USA.

Share on Social Networks: